Visivasnc/iStock via Getty Images Revance Therapeutics ( NASDAQ: RVNC ) plunged 16% in after hours trading after the company disclosed that there's substantial doubt about its ability to contine as a "going concern." The company also missed Q3 revenue estimates and withdrew its 2024 guidance and.
Back to Health Page
